First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS ^G12C Solid Tumors (KRYSTAL-1).

Autor: Ou SI; University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center, Orange, CA., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Leal TA; University of Wisconsin Carbone Cancer Center, Madison, WI., Rybkin II; Henry Ford Cancer Institute, Detroit, MI., Sabari JK; Perlmutter Cancer Center New York University Langone Health, New York, NY., Barve MA; Mary Crowley Cancer Center, Dallas, TX., Bazhenova L; University of California San Diego, Moores Cancer Center, La Jolla, CA., Johnson ML; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN., Velastegui KL; Mirati Therapeutics, Inc, San Diego, CA., Cilliers C; Mirati Therapeutics, Inc, San Diego, CA., Christensen JG; Mirati Therapeutics, Inc, San Diego, CA., Yan X; Mirati Therapeutics, Inc, San Diego, CA., Chao RC; Mirati Therapeutics, Inc, San Diego, CA., Papadopoulos KP; START San Antonio, San Antonio, TX.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Aug 10; Vol. 40 (23), pp. 2530-2538. Date of Electronic Publication: 2022 Feb 15.